Meet lymphoma expert Michael Wang, M.D.

Endoscopic Fusion Overview & Rationale - Michael Y. Wang, M.D.Подробнее

A novel WINDOW of opportunity for young mantle cell lymphoma patientsПодробнее

Michael Wang, MD, Discusses the SYMPATICO Study on Ibrutinib Plus Venetoclax in MCLПодробнее

Dr. Wang on the Evolution of Treatment in MCLПодробнее

Michael Wang, MD, shares details from the ZUMA-2 trial in mantle cell lymphoma presented at ASH 2019Подробнее

The potential of CAR-T therapy in MCLПодробнее

Michael Wang, MD, speculates on therapies for front-line and relapsed mantle cell lymphomaПодробнее

The Evolution of the MIS TILF by Dr. Michael WangПодробнее

Michael Wang, MD, on the distinct advantages of zanubrutinib in the management of lymphomaПодробнее

Dr Michael Wang Outlines Progress With Chemo-Free Therapies to Treat MCLПодробнее

Meet lymphoma oncologist Jason Westin, M.D.Подробнее

Dr. Wang Discusses Promise of Venetoclax in MCLПодробнее

Dr. Wang Discusses the Future of Treatment in MCLПодробнее

Meet lymphoma oncologist Christopher Flowers, M.D.Подробнее

Dr. Wang on Precision Medicine in MCLПодробнее

Striving for Excellence As A Surgeon - Michael Y. Wang, MDПодробнее

Dr Michael Wang on the Coming Precision Medicine Era in Mantle Cell LymphomaПодробнее

Dr. Wang on Acalabrutinib Activity in Mantle Cell LymphomaПодробнее

Dr. Wang on the Efficacy of KTE-X19 in Low- and High-Risk R/R MCLПодробнее